The procedure follows the basic principle of radioimmunoassay where there is competition between the radioactive and non-radioactive antigen for a fixed number of antibody binding sites. The amount of (I-125)-labeled analyte bound to the antibody is inversely proportional to the concentration of unlabeled analyte present. The separation of free and bound antigen is achieved by using a double antibody system.
| Catalog # | KIPI9900 |
| Format | RIA |
| Label | I125 |
| Size | 100 tests |
| Sample Type | Serum, Plasma |
| Sample Volume | 100 µL of extracted sample |
| Controls | 2 levels |
| Range | 25-2500 pg/mL |
| Sensitivity | 20 pg/mL |
| Pretreatment | 300 µL of sample/ 40 min. |
| Incubation | 30min at 37°C + 20min + 20min centrifugation |
| Shelf Life (weeks) | 12 |
Due to local registration requirement, this product can not be sold in Canada, United States, Australia – without prior registration.
For Japan and Brazil, specific registration requirements are necessary. For more information, please contact: regulatory.affairs@diasource.be.
Documents - Download
| Download "Instructions for Use" | KIPI9900.pdf |  |
| Download "Material Safety Data Sheet" | MSKIPI9900.pdf | |
| Download catalogue "RIA" | CATR.pdf | |
| Download RIA Availability Calendar | CALRIA21d.pdf | |
News
Events
Newsletter
